Depomed Says It Was Cheated Out Of Orphan Drug Exclusivity
Depomed Inc. urged a Washington federal judge Friday to force the U.S. Food and Drug Administration to give the company seven years of drug exclusivity for its pain drug Gralise, claiming...To view the full article, register now.
Already a subscriber? Click here to view full article